Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug‐Induced Liver Injury

Tolcapone and entacapone are catechol‐O‐methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson's disease. While both drugs have been shown to cause mitochondrial dysfunction and inhibition of the bile salt export protein (BSEP), liver injury has only been asso...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CPT Pharmacometrics Syst Pharmacol
Hlavní autoři: Longo, DM, Yang, Y, Watkins, PB, Howell, BA, Siler, SQ
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4728295/
https://ncbi.nlm.nih.gov/pubmed/26844013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12053
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky